Copy
View this email in your browser

Doctor Penguin Weekly

5/20/2019
Welcome to the first week for the Doctor Penguin newsletter! This week, we saw Chan et al. build a system that uses speakers and microphones within existing smartphones to detect middle ear fluid by assessing eardrum mobility: the smartphone sends a soft acoustic chirp into the ear canal using the smartphone speaker, detects reflected sound from the eardrum using the smartphone microphone, and uses a logistic regression model to predict middle ear fluid status. In Zhang et al., we saw the application of deep learning to the histopathological diagnosis of urothelial carcinoma at the level of pathologists, with the method interpreting predictions through natural language descriptions and visual attention. We saw Waljee et al. use random forests to generate predictive models of treatment response to ustekinumab, to reliably identify patients with active Crohn disease who were likely to respond to treatment beyond week 42. Finally, we picked up a review of artificial intelligence and machine learning in prostate cancer by Goldenberg et al. Hope you enjoy!

-- Eric Topol & Pranav Rajpurkar  

Quick Links:

  1. Detecting middle ear fluid using smartphones
  2. Pathologist-level interpretable whole-slide cancer diagnosis with deep learning
  3. Development and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn Disease
  4. A new era: artificial intelligence and machine learning in prostate cancer
  5. Cardiovascular disease risk prediction using automated machine learning: A prospective study of 423,604 UK Biobank participants
  6. Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma

Detecting middle ear fluid using smartphones.

 

In Science translational medicine

The presence of middle ear fluid is a key diagnostic marker for two of the most common pediatric ear diseases: acute otitis media and otitis media with effusion. We present an accessible solution that uses speakers and microphones within existing smartphones to detect middle ear fluid by assessing eardrum mobility. We conducted a clinical study on 98 patient ears at a pediatric surgical center. Using leave-one-out cross-validation to estimate performance on unseen data, we obtained an area under the curve (AUC) of 0.898 for the smartphone-based machine learning algorithm. In comparison, commercial acoustic reflectometry, which requires custom hardware, achieved an AUC of 0.776. Furthermore, we achieved 85% sensitivity and 82% specificity, comparable to published performance measures for tympanometry and pneumatic otoscopy. Similar results were obtained when testing across multiple smartphone platforms. Parents of pediatric patients (n = 25 ears) demonstrated similar performance to trained clinicians when using the smartphone-based system. These results demonstrate the potential for a smartphone to be a low-barrier and effective screening tool for detecting the presence of middle ear fluid.

Chan Justin, Raju Sharat, Nandakumar Rajalakshmi, Bly Randall, Gollakota Shyamnath

2019-May-15

Pathologist-level interpretable whole-slide cancer diagnosis with deep learning

In nature machine intelligence

Diagnostic pathology is the foundation and gold standard for identifying carcinomas. However, high inter-observer variability substantially affects productivity in routine pathology and is especially ubiquitous in diagnostician-deficient medical centres. Despite rapid growth in computer-aided diagnosis (CAD), the application of whole-slide pathology diagnosis remains impractical. Here, we present a novel pathology whole-slide diagnosis method, powered by artificial intelligence, to address the lack of interpretable diagnosis. The proposed method masters the ability to automate the human-like diagnostic reasoning process and translate gigapixels directly to a series of interpretable predictions, providing second opinions and thereby encouraging consensus in clinics. Moreover, using 913 collected examples of whole-slide data representing patients with bladder cancer, we show that our method matches the performance of 17 pathologists in the diagnosis of urothelial carcinoma. We believe that our method provides an innovative and reliable means for making diagnostic suggestions and can be deployed at low cost as next-generation, artificial intelligence-enhanced CAD technology for use in diagnostic pathology.

Zizhao Zhang, Pingjun Chen, Mason McGough, Fuyong Xing, Chunbao Wang, Marilyn Bui, Yuanpu Xie, Manish Sapkota, Lei Cui, Jasreman Dhillon, Nazeel Ahmad, Farah K. Khalil, Shohreh I. Dickinson, Xiaoshuang Shi, Fujun Liu, Hai Su, Jinzheng Cai & Lin Yang 

2019-May-13

Development and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn Disease.

In JAMA network open

Importance : Biological therapies have revolutionized inflammatory bowel disease management, but many patients do not respond to biological monotherapy. Identification of likely responders could reduce costs and delays in remission.

Objective : To identify patients with Crohn disease likely to be durable responders to ustekinumab before committing to long-term treatment.

Design, Setting, and Participants : This cohort study analyzed data from 3 phase 3 randomized clinical trials (UNITI-1, UNITI-2, and IM-UNITI) conducted from 2011 to 2015. Participants (n = 401) were individuals with active (C-reactive protein [CRP] measurement of ≥5 mg/L at enrollment) Crohn disease who received ustekinumab therapy. Data analysis was performed from November 1, 2017, to June 1, 2018.

Exposures : All included patients were exposed to 1 or more dose of ustekinumab for 8 weeks or more.

Main Outcomes and Measures : Random forest methods were used in building 2 models for predicting Crohn disease remission, with a CRP level lower than 5 mg/dL as a proxy for biological remission, beyond week 42 of ustekinumab treatment. The first model used only baseline data, and the second used data through week 8.

Results : In total, 401 participants, with a mean (SD) age of 36.3 (12.6) years and 170 male (42.4%), were included. The week-8 model had a mean area under the receiver operating characteristic curve (AUROC) of 0.78 (95% CI, 0.69-0.87). In the testing data set, 27 of 55 participants (49.1%) classified as likely to have treatment success achieved success with a CRP level lower than 5 mg/L after week 42, and 7 of 65 participants (10.8%) classified as likely to have treatment failure achieved this outcome. In the full cohort, 87 patients (21.7%) attained remission after week 42. A prediction model using the week-6 albumin to CRP ratio had an AUROC of 0.76 (95% CI, 0.71-0.82). Baseline ustekinumab serum levels did not improve the model's prediction performance.

Conclusions and Relevance : In patients with active Crohn disease, demographic and laboratory data before week 8 of treatment appeared to allow the prompt identification of likely nonresponders to ustekinumab without the need for costly drug-level monitoring.

Waljee Akbar K, Wallace Beth I, Cohen-Mekelburg Shirley, Liu Yumu, Liu Boang, Sauder Kay, Stidham Ryan W, Zhu Ji, Higgins Peter D R

2019-May-03

A new era: artificial intelligence and machine learning in prostate cancer.

In Nature reviews. Urology

Artificial intelligence (AI) - the ability of a machine to perform cognitive tasks to achieve a particular goal based on provided data - is revolutionizing and reshaping our health-care systems. The current availability of ever-increasing computational power, highly developed pattern recognition algorithms and advanced image processing software working at very high speeds has led to the emergence of computer-based systems that are trained to perform complex tasks in bioinformatics, medical imaging and medical robotics. Accessibility to 'big data' enables the 'cognitive' computer to scan billions of bits of unstructured information, extract the relevant information and recognize complex patterns with increasing confidence. Computer-based decision-support systems based on machine learning (ML) have the potential to revolutionize medicine by performing complex tasks that are currently assigned to specialists to improve diagnostic accuracy, increase efficiency of throughputs, improve clinical workflow, decrease human resource costs and improve treatment choices. These characteristics could be especially helpful in the management of prostate cancer, with growing applications in diagnostic imaging, surgical interventions, skills training and assessment, digital pathology and genomics. Medicine must adapt to this changing world, and urologists, oncologists, radiologists and pathologists, as high-volume users of imaging and pathology, need to understand this burgeoning science and acknowledge that the development of highly accurate AI-based decision-support applications of ML will require collaboration between data scientists, computer researchers and engineers.

Goldenberg S Larry, Nir Guy, Salcudean Septimiu E

2019-May-15

Cardiovascular disease risk prediction using automated machine learning: A prospective study of 423,604 UK Biobank participants.

In PloS one

BACKGROUND : Identifying people at risk of cardiovascular diseases (CVD) is a cornerstone of preventative cardiology. Risk prediction models currently recommended by clinical guidelines are typically based on a limited number of predictors with sub-optimal performance across all patient groups. Data-driven techniques based on machine learning (ML) might improve the performance of risk predictions by agnostically discovering novel risk predictors and learning the complex interactions between them. We tested (1) whether ML techniques based on a state-of-the-art automated ML framework (AutoPrognosis) could improve CVD risk prediction compared to traditional approaches, and (2) whether considering non-traditional variables could increase the accuracy of CVD risk predictions.

METHODS AND FINDINGS : Using data on 423,604 participants without CVD at baseline in UK Biobank, we developed a ML-based model for predicting CVD risk based on 473 available variables. Our ML-based model was derived using AutoPrognosis, an algorithmic tool that automatically selects and tunes ensembles of ML modeling pipelines (comprising data imputation, feature processing, classification and calibration algorithms). We compared our model with a well-established risk prediction algorithm based on conventional CVD risk factors (Framingham score), a Cox proportional hazards (PH) model based on familiar risk factors (i.e, age, gender, smoking status, systolic blood pressure, history of diabetes, reception of treatments for hypertension and body mass index), and a Cox PH model based on all of the 473 available variables. Predictive performances were assessed using area under the receiver operating characteristic curve (AUC-ROC). Overall, our AutoPrognosis model improved risk prediction (AUC-ROC: 0.774, 95% CI: 0.768-0.780) compared to Framingham score (AUC-ROC: 0.724, 95% CI: 0.720-0.728, p < 0.001), Cox PH model with conventional risk factors (AUC-ROC: 0.734, 95% CI: 0.729-0.739, p < 0.001), and Cox PH model with all UK Biobank variables (AUC-ROC: 0.758, 95% CI: 0.753-0.763, p < 0.001). Out of 4,801 CVD cases recorded within 5 years of baseline, AutoPrognosis was able to correctly predict 368 more cases compared to the Framingham score. Our AutoPrognosis model included predictors that are not usually considered in existing risk prediction models, such as the individuals' usual walking pace and their self-reported overall health rating. Furthermore, our model improved risk prediction in potentially relevant sub-populations, such as in individuals with history of diabetes. We also highlight the relative benefits accrued from including more information into a predictive model (information gain) as compared to the benefits of using more complex models (modeling gain).

CONCLUSIONS : Our AutoPrognosis model improves the accuracy of CVD risk prediction in the UK Biobank population. This approach performs well in traditionally poorly served patient subgroups. Additionally, AutoPrognosis uncovered novel predictors for CVD disease that may now be tested in prospective studies. We found that the "information gain" achieved by considering more risk factors in the predictive model was significantly higher than the "modeling gain" achieved by adopting complex predictive models.

Alaa Ahmed M, Bolton Thomas, Di Angelantonio Emanuele, Rudd James H F, van der Schaar Mihaela

2019

Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma.

In Scientific reports

In the context of precision medicine with immunotherapies there is an increasing need for companion diagnostic tests to identify potential therapy responders and avoid treatment coming along with severe adverse events for non-responders. Here, we present a retrospective case study to discover image-based signatures for developing a potential companion diagnostic test for ipilimumab (IPI) in malignant melanoma. Signature discovery is based on digital pathology and fully automatic quantitative image analysis using virtual multiplexing as well as machine learning and deep learning on whole-slide images. We systematically correlated the patient outcome data with potentially relevant local image features using a Tissue Phenomics approach with a sound cross validation procedure for reliable performance evaluation. Besides uni-variate models we also studied combinations of signatures in several multi-variate models. The most robust and best performing model was a decision tree model based on relative densities of CD8+ tumor infiltrating lymphocytes in the intra-tumoral infiltration region. Our results are well in agreement with observations described in previously published studies regarding the predictive value of the immune contexture, and thus, provide predictive potential for future development of a companion diagnostic test.

Harder Nathalie, Schönmeyer Ralf, Nekolla Katharina, Meier Armin, Brieu Nicolas, Vanegas Carolina, Madonna Gabriele, Capone Mariaelena, Botti Gerardo, Ascierto Paolo A, Schmidt Günter

2019-May-15

Follow Us on http://doctorpenguin.com/






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
Stanford · 353 Serra Mall · Stanford, CA 94305-5008 · USA

Email Marketing Powered by Mailchimp